Dörr U, Räth U, Schürmann G, Höring E, Bach D, Wurm K, Scholz M, Adrian H J, Bihl H
Klinik für Nuklearmedizin, Katharinenhospital, Stuttgart.
Rofo. 1993 Jan;158(1):67-73. doi: 10.1055/s-2008-1032604.
Scintigraphy with a radiolabelled somatostatin analog represents a new highly specific approach in the diagnostic work-up of receptor-positive APUD tumours and their metastases. We present our preliminary results with somatostatin receptor scintigraphy in 15 patients with histologically proven midgut carcinoid. 5 out of 6 primary tumour sites (83%) and 90% of the known metastatic lesions could be detected; unknown metastatic lesions were seen in 5 patients. Compared with other nuclear medicine procedures somatostatin receptor scintigraphy is able to detect all tumour sites within hours. This advantage will promote the acceptance of this sensitive and specific imaging modality by the clinicians with regard to preoperative work-up and symptomatic therapy with a somatostatin analog.
用放射性标记的生长抑素类似物进行闪烁扫描代表了一种用于受体阳性APUD肿瘤及其转移灶诊断检查的全新高度特异性方法。我们展示了对15例经组织学证实的中肠类癌患者进行生长抑素受体闪烁扫描的初步结果。6个原发性肿瘤部位中的5个(83%)以及90%的已知转移灶能够被检测到;5例患者发现了未知转移灶。与其他核医学检查方法相比,生长抑素受体闪烁扫描能够在数小时内检测到所有肿瘤部位。这一优势将促使临床医生在术前检查以及使用生长抑素类似物进行对症治疗方面接受这种敏感且特异的成像方式。